BriaCell shareholders ratify MNP as auditor and re-elect all seven director nominees at AGM

BriaCell Therapeutics Corp.

Ratified MNP LLP as independent auditor with 5,346,102 For, 0 Against, 28,968 Withheld.
Re-elected all seven directors: Gross, Lustig, Bondarenko, Williams, Taub, Embro-Pantalony, Schmieg.
Voter turnout: 5,375,071 common shares represented (33.6% of 15,981,726 outstanding shares) – quorum met.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

BriaCell Therapeutics Corp. shareholders approved Ratification of appointment of MNP LLP as auditors at the 2024-01-30 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2024-01-30

Exact text from the filing

Proposal 1. At the Meeting, the shareholders ratified the appointment of MNP LLP as auditors for the Company and the authorization of the Board of Directors of the Company (the "Board") to fix the auditors' remuneration and terms of engagement.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

BriaCell Therapeutics Corp. shareholders approved Election of seven director nominees at the 2024-01-30 meeting.

Proposal: director election
Outcome: passed
Meeting: 2024-01-30

Exact text from the filing

Proposal 2. At the Meeting, the terms of seven (7) members of the Board expired. Each of the seven (7) nominees for director (the "Nominees") were elected to serve until the next annual meeting of shareholders, or until his/her successor is duly elected or appointed, unless he/she resigns, is removed, or becomes disqualified in accordance with the Articles of Incorporation of the Company or the British Columbia Corporations Act.

View on SEC.gov

Browse all shareholder votes →

BriaCell Therapeutics Corp. filing history →

Source: SEC EDGAR

accession 0001493152-24-004525

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.